Members of a key reimbursement policy panel on December 6 continued to push for the creation of separate generic price bands for both middle and lower bands under the current three price-band grouping rule as a way to address unreasonable…
To read the full story
Related Article
- JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
July 16, 2019
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
BUSINESS
- AstraZeneca, Hitachi to Jointly Research Pathogenesis and Prognosis of COPD
December 12, 2019
- Teribone Autoinjector Hits Shelves
December 12, 2019
- Eisai Set to Renovate Tsukuba Research Laboratories, Aims for Completion by March 2023
December 12, 2019
- Otsuka Pharmaceutical Names Executive Deputy President Inoue as New Chief
December 12, 2019
- Astellas Charging Ahead with Immuno-Oncology Initiative to Save Non-Responders: Chief
December 11, 2019
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…